AMAA Journal - Statin myopathy: a brief review
The controversy surrounding the highly promoted cholesterol-lowering drug Vytorin continued Friday when U.S. health officials said they would review the medication’s effectiveness, but only after final trial results were completed.
a combination of two cholesterol drugs — had little medical benefit.
“We have not yet received a final study report and can’t explain why Vytorin didn’t lead to lesser amounts of plaque compared to patients treated with simvastatin alone,” Dr. John Jenkins, director of the FDA’s Office of New Drugs, Center for Drug Evaluation and Research, said during an afternoon teleconference.
Most Popular
When T Make Job Transfers: Good Reasons For Quitting Your Job
10 Jobs That Pay $30 An Hour
Five Ways To Successfully Negotiate A Salary
Today’s Best Part-Time Jobs
Eight Major Job Trends For 2008
a combination of the Zocor (simvastatin) and Zetia (ezetimibe) — may be no more effective at reducing the build-up of plaque in the arteries than Zocor alone. About 60 percent of U.S. patients who are taking Zetia now receive the drug as part of Vytorin.
The FDA expects to receive the final report …
Read the full article with a Free Trial at MyWire.
